66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
July 2025 in “Dermatology Reports” Mesenchymal stem cell therapy shows promise for treating certain inflammatory skin diseases, but more research is needed.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
15 citations
,
January 2006 in “British Journal of Dermatology” A woman with skin eruptions and hair loss improved significantly with ointment treatment.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
November 2024 in “Rheumatology Advances in Practice” Monitor for early signs of azathioprine toxicity and check blood counts regularly.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.